Ogechukwu Ezike

Dr. Ogechukwu Ezike

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
PGPatricia GiglioAyers
Patricia GiglioAyers
OEOgechukwu Ezike
Ogechukwu Ezike
CFChristine E. Foley
Christine E. Foley
BBBenjamin P. Brown
Benjamin P. Brown

29 April 2025 in Current Opinion in Obstetrics and Gynecology
Verified
Journal Article
Closed access
OEOgechukwu Ezike
Ogechukwu Ezike
RSRebecca Schneyer
Rebecca Schneyer
KWKelly Wright
Kelly Wright
KHKacey Hamilton
Kacey Hamilton
Purpose of review: Although fibroids are understood to be a predominantly benign and common pathology, they can have significant impacts on patients’ quality of life and reproductive health. This review summarizes the impact of uterine fibroids on fertility and spontaneous abortion, while also addressing how the treatment for fibroids can affect fertility. Lastly, the review will address strategies for preconception management of fibroids to optimize patients’ reproductive health. Recent findings: The data regarding the impact of fibroids on fertility and pregnancy loss is evolving. However, it is agreed that the impact of fibroids is predominantly determined by their location in the uterus. Fibroids located in the submucosal layer or otherwise disrupting the endometrial cavity can impede the implantation of an embryo or potentially increase the risk of spontaneous abortion. When treating fibroids for the purpose of fertility, surgical management is preferred over medication management. There is limited data supporting procedures such as uterine artery embolization or radiofrequency ablation for the management of fibroids to improve fertility. Surgical management of fibroids not impacting the uterine cavity remains controversial. Summary: Uterine fibroids can have a detrimental impact on fertility and therefore require purposeful attention to both the diagnosis and management of the condition in reproductive-aged women. The treatment of fibroids for the purpose of fertility alone remains controversial. Regardless, fibroid size and location should be cataloged, and surgical management should be offered to patients experiencing difficulties with conception.

6 July 2026 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
RSRebecca Schneyer
Rebecca Schneyer
RMRaanan Meyer
Raanan Meyer
OEOgechukwu Ezike
Ogechukwu Ezike
CLConnie Liao
Connie Liao
KWKelly Wright
Kelly Wright
MSMatthew Thomas Siedhoff
Matthew Thomas Siedhoff

21 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGrace Pipes
Grace Pipes
RSRebecca J. Schneyer
Rebecca J. Schneyer
KHKacey M. Hamilton
Kacey M. Hamilton
OEOgechukwu Ezike
Ogechukwu Ezike
KCKatharine Ciesielski
Katharine Ciesielski
MSMatthew Thomas Siedhoff
Matthew Thomas Siedhoff
Background/Objective: Ketorolac is an effective alternative and addition to opioids for postoperative pain control; however, there is concern of perioperative bleeding risk with its use. Within gynecology, this risk has not yet been explored in the context of hysterectomy. This study aimed to evaluate the risk of postoperative bleeding complications with ketorolac administration in the context of hysterectomy. Methods: This was a retrospective cohort study that included all patients who underwent hysterectomy for benign indications between 2015 and 2024 at a quaternary care academic hospital. Inclusion criteria were any type of hysterectomy during the study period, while exclusion criteria were malignancy and peripartum status. Complication data for up to thirty days post operation were collected. Multivariable regression analysis, including age, American Society of Anesthesiology category, use of celecoxib before surgery, anticoagulant treatment, uterus size, surgical approach, increased surgical complexity, and lysis of adhesions, was performed to identify the adjusted odds of postoperative bleeding complications. The primary outcome was a composite of any postoperative bleeding complications by use of postoperative ketorolac, including postoperative transfusion, readmission, or reoperation for bleeding. Results: In total, 4236 patients underwent hysterectomy for benign indications during our study period, of which 76% (n = 3236) received ketorolac postoperatively. The composite postoperative bleeding rate was lower in the ketorolac group (2.1% vs. 4.1%, p = 0.001). There was no association between ketorolac use and risk of postoperative bleeding in multivariable regression analysis (aOR 1.02, 95% CI 0.36–2.88). There was no difference in overall intraoperative or perioperative complications (p = 0.070 for both). Major perioperative complications were less likely in the ketorolac group (p = 0.046). Additionally, there were no differences in postoperative complications except for ileus, which was less likely in the ketorolac group (p = 0.034). Conclusions: Ketorolac administration was not associated with a higher risk of bleeding complications after hysterectomy, including when celecoxib was used preoperatively as part of an enhanced recovery protocol. It may safely be administered as an opioid-sparing pain medication in this setting.